CSIMarket
 


Checkmate Pharmaceuticals Inc   (CMPI)
Other Ticker:  
 

Cumulative Checkmate Pharmaceuticals Inc 's Quick Ratio for Trailing Twelve Months Period

CMPI's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

CMPI Quick Ratio for Trailing Twelve Months Period

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Current Liabilities Growth 63.34 % 19.1 % -11.83 % -4.05 % -
Y / Y Cash & cash equivalent Growth -30.03 % -25.31 % -41.13 % 6.3 % -
Quick Ratio for Trailing Twelve Months Period 8.29 10.35 11.68 13.12 12.84
Total Ranking # 566 # 461 # 332 # 268 # 237
Seq. Current Liabilities Growth 27.33 % 20.06 % 16.56 % -8.33 % -7.16 %
Seq. Cash & cash equivalent Growth -15.28 % -12.34 % -5.28 % -0.54 % -9.56 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2022
On the trailing twelve months basis Due to growth in Current Liabilities in the I. Quarter to $12 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 8.29 below Checkmate Pharmaceuticals Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 101 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Checkmate Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about CMPI
Quick Ratio CMPI in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 102
Sector # 510
S&P 500 # 877


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
13.12 10.95 8.29
(Jun 30 2021)   (Mar 31 2022)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Icosavax Inc   22.18 
Fusion Pharmaceuticals Inc   21.97 
Crispr Therapeutics Ag  21.59 
Humacyte Inc   19.61 
Elevation Oncology inc   19.02 
4d Molecular Therapeutics Inc   18.91 
Inmune Bio Inc   17.73 
Miromatrix Medical inc   16.99 
Kymera Therapeutics Inc   16.86 
Achilles Therapeutics Plc  16.85 
Ocugen Inc   16.85 
Century Therapeutics inc   16.68 
Forma Therapeutics Holdings Inc.  16.54 
Solid Biosciences Inc   16.01 
Adverum Biotechnologies Inc   15.81 
In8bio Inc   15.64 
Curis Inc   15.48 
Tcr2 Therapeutics Inc   15.32 
Tarsus Pharmaceuticals Inc   15.23 
Anavex Life Sciences Corp   15.22 
Immunovant Inc   14.98 
Kodiak Sciences Inc   14.80 
Omega Therapeutics Inc   14.69 
Arcellx Inc   14.62 
Krystal Biotech Inc   14.49 
Aptose Biosciences Inc   13.72 
Springworks Therapeutics Inc   13.57 
Candel Therapeutics Inc   13.51 
Jounce Therapeutics inc   12.61 
Atyr Pharma Inc   12.54 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com